Guerbet SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Guerbet SA Announces FY 2012 Dividend Proposal
Guerbet SA announced that it will submit a proposal to the general meeting of May 24, 2013 for payment of a dividend of EUR 2 per share for full year 2012, representing a payout ratio of 2.08% based on the share price of 31 December 2012.
Latest Developments for Guerbet SA
- Guerbet SA announces ANSM approval of Lipiodol Ultra-Fluid for visualization, localization and vectorization of hepatocellular carcinoma during trans-arterial chemoembolization
- Guerbet SA reaffirms FY 2014 revenue guidance
- Guerbet SA announces FDA approves Lipiodol (Ethiodized Oil) injection for imaging of tumors in adults
- Guerbet SA proposes FY 2013 dividend and issues FY 2014 financial guidance
Latest Key Developments in Pharmaceuticals
- Aastrom Biosciences Inc announces closing of public offering of common stock and full exercise of underwriters' option to purchase additional shares
- Tokai Pharmaceuticals Inc announces pricing of initial public offering
- QLT Inc provides update on merger with Auxilium Pharmaceuticals Inc
- Gilead Sciences Inc announces data from phase 2 study of Simtuzumab for previously untreated pancreatic cancer
- Share this
- Digg this